Stay updated with breaking news from Esistant Htn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following recent FDA approval of two renal denervation systems for the treatment of hypertension, experts speculate on which patients will be prioritized for the procedure.
After a positive FDA panel review in August, the FDA has approved the Paradise Ultrasound Renal Denervation system for the treatment of hypertension, manufacturer Recor and parent company Otsuka announced.
The findings provide support for potentially using aprocitentan in patients with BP that remains elevated despite treatment with three established antihypertensive drug classes and with stage 3 CKD.
A World Health Organization report indicates that simple and cheap medications and care are not being used and that most patients receiving treatment do not have controlled blood pressure.
Long-term blood pressure reductions in the Black patient cohort of the SYMPLICITY HTN-3 renal denervation trial challenge early results.